Prot #CC-10004-AS-001: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Active Ankylosing Spondylitis

Project: Research project

Project Details

StatusFinished
Effective start/end date10/23/12 → 10/23/15

Funding

  • PPD Development (Prot # CC-10004-AS-001 // Prot # CC-10004-AS-001)
  • Celgene Corporation (Prot # CC-10004-AS-001 // Prot # CC-10004-AS-001)